J Korean Acad Periodontol.  2009 Sep;39(3):359-365. 10.5051/jkape.2009.39.3.359.

Response of fetal rat calvarial cells on mineral trioxide aggregate after IL-1beta stimulation

• Lee SH
• Park JI
• Kim YJ

• KMID: 2212150
• DOI: http://doi.org/10.5051/jkape.2009.39.3.359

Abstract

PURPOSE
The purpose of this study was to investigate the ability of Mineral trioxide aggregate(MTA) to support osteoclastic differentiation from fetal rat calvarial cell.
METHODS
In this study, response of IL-6, RANKL, and OPG in fetal rat calvarial cells stimulated with IL-1beta on MTA was evaluated by ELISA and RT-PCR.
RESULTS
The results were as follows; there was no significant difference between glass and MTA at 5days. In ELISA analysis, Glass group and MTA group showed similar IL-6 expression, Glass+IL-1beta group and MTA+IL-1beta group showed similar IL-6 expression. In RT-PCR analysis, Glass group and MTA group showed similar IL-6, RANKL, OPG mRNA expression, MTA+IL-1beta group and Glass+IL-1beta group showed 3 fold increase of IL-6 and RNAKL mRNA expression when compared with MTA group. All groups showed similar OPG mRNA expression.
CONCLUSIONS
MTA does not suppress cell proliferation and increase the proinflammatory cytokine that induce osteoclastogenesis. Thus, MTA is biocompatible material that could be used in various clinical conditions.

Keyword

biocompatible materials; cytokines; ELISA; mineral trioxide aggregate

MeSH Terms

Aluminum Compounds
Animals
Biocompatible Materials
Calcium Compounds
Cell Proliferation
Cytokines
Drug Combinations
Enzyme-Linked Immunosorbent Assay
Glass
Glutamates
Guanine
Interleukin-6
Osteoclasts
Oxides
Rats
RNA, Messenger
Silicates
Pemetrexed
Aluminum Compounds
Biocompatible Materials
Calcium Compounds
Cytokines
Drug Combinations
Glutamates
Guanine
Interleukin-6
Oxides
RNA, Messenger
Silicates

Figure

• 

  Figure 1 Cell proliferation assay after 3 days and 5 days of culture on glass and MTA. *: significantly different compared to glass at day 3 (p<0.05).

• 

  Figure 2 Mean concentration of IL-6 in glass, MTA, MTA+IL-1β, glass+IL-1β. *: Significantly different to Glass at day 1 (p<0.05). †: Significantly different to MTA only at day 1 (p<0.05). §: Significantly different to Glass at day 3 (p<0.05).

• 

  Figure 3 Reverse transcription-polymerase chain reaction (RTc-PCR) analysis of IL-6, RANKL and OPG mRNA expression related to GAPDH means in rat calvarial cells.

Reference

1. Torabinejad M, Hong CU, McDonald F, Pitt Ford TR. Physical and chemical properties of a new root-end filling material. J Endod. 1995. 21:349–353.

2. Koh ET, McDonald F, Pitt Ford TR, Torabinejad M. Cellular response to Mineral Trioxide Aggregate. J Endod. 1998. 24:543–547.

3. Robert HW, Toth JM, Berzins DW, Charlton DG. Mineral trioxide aggregate material use in endodontic treatment: a review of the literature. Dent Mater. 2008. 24:149–164.

4. Zhu Q, Haglund R, Safavi KE, Spangberg LSW. Adhesion of human osteoblasts on root-end filling materials. J Endod. 2000. 26:404–406.

5. Torabinejad M, Hong CU, Pitt Ford TR, Kettering JD. Cytotoxicity of four root-end filling materials. J Endod. 1995. 21:489–492.

6. Pelliccioni GA, Ciapetti G, Cenni E, Granchi D, Nanni M, Pagani S, Giunti A. Evaluation of osteoblast-like cell response to ProRoot MTA cement. J Mat Sci. 2004. 15:167–173.

7. Yavuzyilmaz E, Yamalik N, Bulut S, Ozen S, Ersoy F, Saatci U. The gingival crevicular fluid interleukin-1beta and tumor necrosis factor-a levels in patients with rapidly progressive periodontitis. Aust Dent J. 1995. 40:46–49.

8. Tsai CC, Hou YP, Chen CC. Levels of interleukin-1beta and interleukin-8 in gingival crevicular fluid in adult periodontitis. J Periodontol. 1995. 66:852–859.

9. Ishihara Y, Kuroyagani T, Shirozi N, Yamagishi E, Ohguchi M, Koide M, Ueda N, Amano K, Noguchi T. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. J Periodont Res. 1997. 32:524–529.

10. Giannopoulou C, Kama JJ, Mombelli A. Effect of inflammation, smoking, and stress on gingival, crevicular fluid cytokine level. Journal of Clinical Periodontology. 2003. 30:145–153.

11. Barrieshi-Nusair K, Qudeimat MA. A prospective clinical study of mineral trioxide aggregate for partial pulpotomy in cariously exposed permanent teeth. J Endod. 2006. 32:731–735.

12. Cory AH, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991. 3:207–212.

13. Nakayama A, Ogiso B, Tanabe N, Takeichi O, Matsuzaka K, Inoue T. Behaviour of bone marrow osteoblasts-like cells on mineral trioxide aggregate: morphology and expression of type 1 collagen and bone-related protein mRNAs. Int Endodont J. 2005. 38:203–210.

14. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand : Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 2000. 275:768–775.

15. Hofbaur LC, Heufelder AE. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001. 79:243–253.

16. Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U, Hein G, Hufner M. Cytokine, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone disease. J Bone Miner Res. 2003. 18:529–538.

17. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 2001. 20:1271–1280.

18. Lerner UH. Inflammation-induced bone remodeling in periodontal disease and the influence of post menopausal osteoporosis. J Dent Res. 2006. 85:596–607.

19. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003. 423:337–342.

20. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol. 2008. 79:Suppl. 1569–1576.

21. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytoline Growth Factor Rev. 2002. 13:357–368.

22. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucan LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun. 1996. 64:3231–3235.